Keen to turn a new page, In­di­v­ior branch­es out, pick­ing up an op­tion for cannabis ad­dic­tion drug

Hav­ing put the scan­dal around its flag­ship opi­oid ad­dic­tion drug be­hind it, In­di­v­ior is branch­ing out the sub­stance abuse port­fo­lio.

The lat­est ad­di­tion comes in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER